Kanawha Capital Management’s GSK GSK Stock Holding History

Kanawha Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,458	Closed	-$388K	–	221
2023 Q4	$388K	Sell	10,458 -13,725	-57%	-$493K	0.04%	162
2023 Q3	$877K	Sell	24,183 -928	-4%	-$32.9K	0.08%	113
2023 Q2	$895K	Sell	25,111 -440	-2%	-$15.8K	0.08%	113
2023 Q1	$909K	Sell	25,551 -5,377	-17%	-$188K	0.09%	111
2022 Q4	$1.09M	Sell	30,928 -3,380	-10%	-$113K	0.11%	104
2022 Q3	$1.01M	Sell	34,308 -606	-2%	-$23K	0.11%	103
2022 Q2	$1.9M	Sell	34,914 -159	-0.5%	-$8.78K	0.19%	83
2022 Q1	$1.91M	Sell	35,073 -872	-2%	-$47.4K	0.17%	87
2021 Q4	$1.98M	Sell	35,945 -1,318	-4%	-$68.6K	0.17%	86
2021 Q3	$1.78M	Sell	37,263 -2,055	-5%	-$103K	0.16%	89
2021 Q2	$1.96M	Sell	39,318 -1,572	-4%	-$75.5K	0.18%	85
2021 Q1	$1.82M	Sell	40,890 -4,068	-9%	-$185K	0.18%	84
2020 Q4	$2.07M	Sell	44,958 -2,389	-5%	-$110K	0.21%	78
2020 Q3	$2.23M	Buy	47,347 +1,105	+2%	+$55.4K	0.26%	74
2020 Q2	$2.36M	Sell	46,242 -327	-0.7%	-$16.8K	0.29%	72
2020 Q1	$2.21M	Buy	46,569 +331	+0.7%	+$17.7K	0.32%	71
2019 Q4	$2.72M	Buy	46,238 +2,885	+7%	+$160K	0.32%	73
2019 Q3	$2.31M	Buy	43,353 +707	+2%	+$36.4K	0.3%	73
2019 Q2	$2.13M	Buy	42,646 +3,756	+10%	+$188K	0.29%	75
2019 Q1	$2.03M	Buy	38,890 +3,483	+10%	+$174K	0.29%	74
2018 Q4	$1.69M	Buy	35,407 +2,622	+8%	+$129K	0.26%	75
2018 Q3	$1.65M	Buy	32,785 +2,283	+7%	+$116K	0.23%	78
2018 Q2	$1.54M	Buy	30,502 +223	+0.7%	+$11.2K	0.23%	79
2018 Q1	$1.48M	Sell	30,279 -230	-0.8%	-$10.7K	0.22%	80
2017 Q4	$1.35M	Sell	30,509 -2,656	-8%	-$123K	0.2%	84
2017 Q3	$1.68M	Sell	33,165 -697	-2%	-$35.4K	0.26%	79
2017 Q2	$1.82M	Sell	33,862 -458	-1%	-$24.4K	0.28%	78
2017 Q1	$1.81M	Buy	34,320 +22	+0.1%	+$1.12K	0.29%	77
2016 Q4	$1.65M	Sell	34,298 -8,964	-21%	-$443K	0.28%	76
2016 Q3	$2.33M	Sell	43,262 -78	-0.2%	-$4.28K	0.39%	71
2016 Q2	$2.35M	Sell	43,340 -178	-0.4%	-$9.38K	0.39%	71
2016 Q1	$2.21M	Sell	43,518 -337	-0.8%	-$16.8K	0.38%	71
2015 Q4	$2.21M	Sell	43,855 -298	-0.7%	-$15.2K	0.4%	68
2015 Q3	$2.12M	Buy	44,153 +2,003	+5%	+$104K	0.41%	68
2015 Q2	$2.19M	Buy	42,150 +27	+0.1%	+$1.52K	0.39%	74
2015 Q1	$2.43M	Buy	42,123 +2,931	+7%	+$168K	0.43%	69
2014 Q4	$2.09M	Buy	39,192 +6,410	+20%	+$359K	0.37%	75
2014 Q3	$1.88M	Buy	32,782 +2,816	+9%	+$173K	0.34%	79
2014 Q2	$2M	Buy	29,966 +4,473	+18%	+$303K	0.37%	79
2014 Q1	$1.7M	Buy	25,493 +440	+2%	+$29.7K	0.32%	79
2013 Q4	$1.67M	Sell	25,053 -137	-0.5%	-$8.88K	0.32%	81
2013 Q3	$1.58M	Buy	25,190 +3,406	+16%	+$219K	0.33%	81
2013 Q2	$1.36M	Buy	+21,784	New	+$1.38M	0.3%	81

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kanawha Capital Management's GSK Position: Q1 2024 in Review

Kanawha Capital Management sold out of GSK (GSK) in Q1 2024, closing a stake of 10,458 shares — an estimated $388K sold.

Kanawha Capital Management first reported a position in GSK in Q2 2013 and held it in 43 quarters. The position peaked at $2.72M in Q4 2019. 910 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

Kanawha Capital Management reported no remaining GSK position as of Q1 2024 after selling out during the quarter.
Kanawha Capital Management sold 10,458 GSK shares in Q1 2024, an estimated $388K.
Kanawha Capital Management first reported a position in GSK in Q2 2013 and held it in 43 quarters.
Kanawha Capital Management's GSK position peaked at $2.72M in Q4 2019.
910 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on Kanawha Capital Management's 13F filing for Q1 2024, filed 29 Apr 2024.